IVERIC bio Gelecekteki Büyüme

Future kriter kontrolleri 5/6

IVERIC bio kazanç ve gelirin sırasıyla yıllık 59% ve 58% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 61.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -21.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

59.0%

Kazanç büyüme oranı

61.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.5%
Gelir büyüme oranı	58.0%
Gelecekteki özkaynak getirisi	-21.7%
Analist kapsamı	Good
Son güncelleme	23 Jun 2023

Gelecekteki son büyüme güncellemeleri

Recent updates

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Sep 06

IVERIC bio Q2 2022 Earnings Preview

Jul 25

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

Jul 05

IVERIC bio: A First Take

Jun 23

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

May 20

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Feb 01

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Jul 02

IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses

Jun 18

IVERIC bio EPS misses by $0.04

May 05

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Mar 12

We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth

Nov 27

IVERIC bio EPS misses by $0.05

Nov 02

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:ISEE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	365	-28	57	N/A	9
12/31/2024	124	-200	-131	-154	9
12/31/2023	11	-281	-212	-236	8
3/31/2023	N/A	-223	-178	-177	N/A
12/31/2022	N/A	-185	-165	-164	N/A
9/30/2022	N/A	-159	-138	-137	N/A
6/30/2022	N/A	-141	-123	-122	N/A
3/31/2022	N/A	-122	-107	-107	N/A
12/31/2021	N/A	-115	-99	-99	N/A
9/30/2021	N/A	-107	-97	-97	N/A
6/30/2021	N/A	-108	-86	-86	N/A
3/31/2021	N/A	-96	-78	-78	N/A
12/31/2020	N/A	-85	-66	-66	N/A
9/30/2020	N/A	-77	-57	-57	N/A
6/30/2020	N/A	-66	-54	-54	N/A
3/31/2020	N/A	-61	-51	-51	N/A
12/31/2019	N/A	-59	-48	-48	N/A
9/30/2019	N/A	63	-47	-47	N/A
6/30/2019	N/A	62	-45	-45	N/A
3/31/2019	N/A	64	-44	-44	N/A
12/31/2018	N/A	63	-42	-42	N/A
9/30/2018	N/A	-51	-45	-45	N/A
6/30/2018	207	153	-50	-50	N/A
3/31/2018	208	144	-72	-72	N/A
12/31/2017	210	114	-122	-122	N/A
9/30/2017	215	57	-142	-141	N/A
6/30/2017	10	-192	-132	-131	N/A
3/31/2017	37	-200	-134	-133	N/A
12/31/2016	51	-193	N/A	-109	N/A
9/30/2016	50	-163	N/A	-115	N/A
6/30/2016	52	-141	N/A	-133	N/A
3/31/2016	26	-149	N/A	-84	N/A
12/31/2015	52	-106	N/A	-79	N/A
9/30/2015	48	-102	N/A	-29	N/A
6/30/2015	85	-54	N/A	-50	N/A
3/31/2015	83	-89	N/A	96	N/A
12/31/2014	41	-117	N/A	111	N/A
9/30/2014	40	-106	N/A	75	N/A
6/30/2014	N/A	-132	N/A	107	N/A
3/31/2014	N/A	-71	N/A	-61	N/A
12/31/2013	N/A	-57	N/A	-49	N/A
9/30/2013	N/A	-42	N/A	-27	N/A
6/30/2013	N/A	-30	N/A	-18	N/A
3/31/2013	N/A	-23	N/A	-13	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ISEE önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.1% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: ISEE önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: ISEE önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: ISEE şirketinin gelirinin (yıllık 58% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ISEE şirketinin gelirinin (yıllık 58% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ISEE 3 yıl içinde kârsız olması bekleniyor.

IVERIC bio Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 12%

Forecast to breakeven in 2025

Price target increased by 10% to US$35.09

Forecast to breakeven in 2025

Consensus revenue estimates fall by 13%

No longer forecast to breakeven

Recent updates

IVERIC bio, Inc. Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy

IVERIC bio, Inc. Files Form 15

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from NASDAQ Composite Index

IVERIC bio's Common Stock Delisted from NASDAQ

Senior VP & COO exercised options and sold US$730k worth of stock

Senior VP & COO notifies of intention to sell stock

Consensus EPS estimates fall by 12%

Forecast to breakeven in 2025

Senior VP exercised options and sold US$2.2m worth of stock

Price target increased by 10% to US$35.09

Forecast to breakeven in 2025

Senior VP notifies of intention to sell stock

Senior VP & COO exercised options and sold US$940k worth of stock

Consensus revenue estimates fall by 13%

Senior VP & COO exercised options and sold US$299k worth of stock

No longer forecast to breakeven

Senior VP & COO exercised options and sold US$314k worth of stock

IVERIC bio, Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Senior VP & COO notifies of intention to sell stock

CEO & Director exercised options and sold US$350k worth of stock

Iveric Bio Announces the Addition of Pravin U. Dugel to Its Board of Directors

Forecast to breakeven in 2025

Iveric Bio, Inc. Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

Senior VP & COO exercised options and sold US$259k worth of stock

Senior VP & COO exercised options to buy US$109k worth of stock.

IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $300.375 million.

President exercised options to buy US$179k worth of stock.

IVERIC bio, Inc. Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

Price target increased to US$30.17

Senior VP & COO exercised options and sold US$964k worth of stock

IVERIC bio, Inc. Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

IVERIC bio, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iveric Bio Announces Positive Topline Data from Zimura® Gather2 Phase 3 Clinical Trial in Geographic Atrophy

Price target increased to US$26.36

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Senior VP & Chief Commercial Officer exercised options and sold US$138k worth of stock

IVERIC bio Q2 2022 Earnings Preview

IVERIC bio, Inc. to Report Q2, 2022 Results on Jul 26, 2022

Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® At American Society of Retina Specialists Meeting

Insider exercised options and sold US$73k worth of stock

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Value Index

IVERIC bio: A First Take

Independent Director recently bought US$241k worth of stock

IVERIC bio, Inc. Announces Presentation of Post-Hoc Analysis At Macula Society from Gather1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

We're Hopeful That IVERIC bio (NASDAQ:ISEE) Will Use Its Cash Wisely

Price target increased to US$24.38

IVERIC bio, Inc. Completes Retrospective Review of Choroidal Neovascularization

IVERIC bio, Inc., Annual General Meeting, May 12, 2022

Senior VP exercised options and sold US$261k worth of stock

Senior VP notifies of intention to sell stock

IVERIC bio, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

IVERIC bio, Inc. Announces in GATHER2, the Company's Phase 3 Clinical Trial Evaluating the Safety and Efficacy of Zimura (Avacincaptad Pegol) for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration

CEO & Director exercised options and sold US$882k worth of stock

CEO & Director exercised options and sold US$122k worth of stock

Insider recently bought US$50k worth of stock

IVERIC bio (NASDAQ:ISEE) Is In A Good Position To Deliver On Growth Plans

Estimating The Intrinsic Value Of IVERIC bio, Inc. (NASDAQ:ISEE)

Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field

Price target increased to US$16.50

IVERIC Bio, Inc. Provides Updates on Clinical Trails

Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation

Price target increased to US$14.67

IVERIC bio, Inc. Updates on Its Phase 3 Clinical Trails Zimura

IVERIC bio discusses GATHER2 enrollment and retention updates and new GATHER1 post-hoc analyses